$MRNA.US$ stock gained 7.8% Thursday, its virtual R&D day, which began at 8 a.m. Eastern. It plans to announce the development of a vaccine candidate that will protect against Covid-19 and the flu, to be known as mRNA-1073. 
Moderna was a very different company at the time of its last virtual R&D day in September of 2020. Still a clinical-stage company at the time, Moderna had no authorized or approved products. That changed months later, when the U.S. Food and Drug Administration authorized Moderna’s Covid-19 vaccine, which is expected to bring in $20.1 billion in revenues this year alone.
Its stock price has been up more than 300% this year. 
Just to mention, another vaccine maker $NVAX.US$ had also initiated an early-stage study to test its combined flu and COVID-19 vaccine. However, the same scenario didn't show on its stock price. Kinda tricky.
Source: Moderna Stock Jumped Because It Just Unveiled a Two-in-One Vaccine for Covid and the Flu

Spoiler: Chance to win points at the end of this post!
Happy Labor Day weekend, mooers! How's your vocation?
Before diving into Weekly Buzz, congrats to the following mooers whose comments were selected as the top comments last week!
@战神鑫爷 @chotomartay @Grandpa Squeeze @HopeAlways @GratefulPanda @Jia Yung @要HoDL @Syuee @Moonew @VCSuccess
Click here to see their great insights!
Notice: 500 points have been sent to you already. Please feel free to contact us if there is any problem....

$PFE.US$
Cross 48 tonight

Semiconductors industry had been a hot pick for the recent year, and among the semiconductor’s counter, I am particularly paying attention to $AVGO.US$. I will briefly go through why I picked $AVGO.US$ to be the next counter to hit historical high from the perspective of Microeconomic, Fundamental Analysis and Technical Analysis.
1. Microeconomic
-Global semiconductors industry is doing well due to the high demand for chips. The advancement of technology devices from ...